A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04486378 |
Recruitment Status :
Recruiting
First Posted : July 24, 2020
Last Update Posted : April 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Stage II Colorectal Cancer Stage III | Drug: RO7198457 intravenous (IV) Other: Observational group (no intervention) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 229 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection |
Actual Study Start Date : | March 8, 2021 |
Estimated Primary Completion Date : | February 2026 |
Estimated Study Completion Date : | July 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: RO7198457
Participants will receive a recommended dose of RO7198457.
|
Drug: RO7198457 intravenous (IV)
RO7198457 administered as an IV injection at protocol-specified intervals over 12 months. |
Observational Group
Observational group will undergo watchful waiting, which is the standard of care in this setting.
|
Other: Observational group (no intervention)
watchful waiting |
Experimental: Biomarker Cohort
15 patients
|
Drug: RO7198457 intravenous (IV)
RO7198457 administered as an IV injection at protocol-specified intervals over 12 months. |
Experimental: Exploratory Cohort
20 patients
|
Drug: RO7198457 intravenous (IV)
RO7198457 administered as an IV injection at protocol-specified intervals over 12 months. |
- Disease-free survival (DFS) [ Time Frame: Through study completion, up to 5 years ]
DFS defined as the time from randomization to occurrence of any of the following events, whichever occurs first:
- Locoregional recurrence or distant metastases as determined by an independent central radiology assessment.
- Occurrence of second primary (same or other) cancer as determined by an independent central radiology assessment.
- Death from any cause.
- Loss to follow-up is censored.
- Relapse-free survival (RFS) [ Time Frame: Through study completion, up to 5 years ]
RFS is defined as the time from randomization to occurrence of any of the following events, whichever occurs first:
- Locoregional recurrence or distant metastases as determined by the investigator.
- Death from any cause.
- Occurrence of second primary (same or other) cancer as determined by the investigator is ignored.
- Loss to follow-up is censored.
- Time to recurrence (TTR) [ Time Frame: Through study completion, up to 5 years ]
TTR is defined as the time from randomization to occurrence of any of the following events (i.e., events related to the same cancer), whichever occurs first:
- Locoregional recurrence or distant metastases as determined by the investigator.
- Death from same cancer.
- Occurrence of second primary (same or other) cancer as determined by the investigator is ignored.
- Loss to follow-up and deaths from other cancer, non-cancer-related deaths, treatment-related deaths are censored.
- Time to treatment failure (TTF) [ Time Frame: Through study completion, up to 5 years ]
TTF is defined as the time from randomization to occurrence of any of the following events, whichever occurs first:
- Locoregional recurrence or distant metastases as determined by the investigator.
- Occurrence of second primary (same or other) cancer as determined by the investigator.
- Death from any cause except non-cancer related death.
- Start of new cancer therapy.
- Loss to follow-up and non-cancer-related deaths are censored.
- Overall survival (OS) [ Time Frame: Through study completion, up to 5 years ]OS defined as the time from randomization to death from any cause.
- Change of ctDNA status (approximately every 3 months) [ Time Frame: Through study completion, up to 5 years ]
- Occurrence of treatment emergent adverse event (TEAE) [ Time Frame: 15 months ]TEAE, including Grade 3+, serious, fatal TEAE by relationship (adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0).
- Occurrence of dose reduction and discontinuation of RO7198457 due to a TEAE. [ Time Frame: 15 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must be a man or woman of at least 18 years of age.
-
Patients must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per American Joint Committee on Cancer 2017 that has been surgically totally resected (R0 confirmed by pathology report). Stage II (high risk) colon cancer is defined as Stage II disease with any of the following risk factors for recurrence:
- T4
- Grade ≥ 3.
- Clinical presentation with bowel obstruction or perforation.
- Histological signs of vascular, lymphatic or perineural invasion.
- < 12 nodes evaluated after surgery.
-
Patients must have detectable ctDNA prior to start of adjuvant chemotherapy (AdCTx) (except for the Biomarker Cohort).
• ctDNA assay must be performed through this trial or study BNT000-001 ctDNA screening protocol.
- Patients must have an Eastern Cooperative Oncology Group Performance Status of 0-1.
- Patients must have adequate hematologic, bone marrow and organ function as defined by the protocol.
- Adequate tumor material in formalin-fixed paraffin embedded blocks or as sectioned tissue (only upon approval by sponsor) must be available (as described in the laboratory manual).
- The patient has started a standard of care AdCTx preferably within 8 weeks but no later than 10 weeks post-surgery and has completed at least 3 months of treatment of a 3- or a 6-month course of chemotherapy (including rest days).
Exclusion Criteria:
- Patients with uncontrolled intercurrent illness as defined by the protocol.
- Diagnosed microsatellite instability high tumors.
-
Prior therapy with any of the following:
- Neo-adjuvant (radio)chemotherapy prior to surgery.
- Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of trial treatment or anticipation of need for systemic immunosuppressive medication during trial treatment, with the exception of low dose steroids defined as 10 mg oral prednisone (or equivalent).
- Current or recent (within the 28 days prior to randomization) treatment with another investigational drug.
- Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.
- Patients who developed metastatic disease during screening/receiving standard of care treatment (not applicable for Exploratory Cohort).
-
Patients with known past or current malignancy other than inclusion diagnosis, except for:
- Cervical carcinoma of Stage 1B or less.
- Non-invasive basal cell or squamous cell skin carcinoma.
- Non-invasive, superficial bladder cancer.
- Prostate cancer with a current prostate-specific antigen level < 0.1 ng/mL.
- Any curable cancer with a complete response of > 2 years duration.
- Patients with known allergies, hypersensitivity, or intolerance to RO7198457 or its excipients.
- Patients who had major surgery (e.g., surgery requiring general anesthesia) within 4 weeks before screening, or will not have fully recovered from surgery, or have surgery planned during the time the patient are expected to participate in the trial.
-
Patients with positive serology for hepatitis B (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy):
- Based on a test for antibodies to hepatitis B core antigens (anti-HBc) and
- Negative test for antibodies to hepatitis B surface antigens (anti-HBs).
- Active Hepatitis C virus (HCV) infection; patients who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
- Patients who have a history of human immunodeficiency virus (HIV) antibody positivity, or tests positive for HIV at screening.
- Patients who have had prior splenectomy.
NOTE: Other protocol defined inclusion/exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04486378
Contact: BioNTech clinical trials patient information | +49 6131 9084 ext 0 | patients@biontech.de |
Study Director: | BioNTech Responsible Person | BioNTech SE |
Responsible Party: | BioNTech SE |
ClinicalTrials.gov Identifier: | NCT04486378 |
Other Study ID Numbers: |
BNT122-01 2020-000451-12 ( EudraCT Number ) U1111-1250-5294 ( Other Identifier: WHO Universal Trial Number (UTN) ) |
First Posted: | July 24, 2020 Key Record Dates |
Last Update Posted: | April 23, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Cancer Colorectal Cancer |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |